<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112861</url>
  </required_header>
  <id_info>
    <org_study_id>ONS-5010-007</org_study_id>
    <nct_id>NCT05112861</nct_id>
  </id_info>
  <brief_title>A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders</brief_title>
  <acronym>NORSE SEVEN</acronym>
  <official_title>A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outlook Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Outlook Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled&#xD;
      syringes in subjects diagnosed with a retinal condition that would benefit from treatment&#xD;
      with intravitreal injection of bevacizumab, including: exudative age-related macular&#xD;
      degeneration, diabetic macular edema, or branch retinal vein occlusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and incidence of treatment-emergent adverse events following intravitreal injections of ONS-5010 in vials or PFS</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Wet Macular Degeneration</condition>
  <condition>BRVO - Branch Retinal Vein Occlusion</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Biological: bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>1.25 mg, intravitreal injection</description>
    <arm_group_label>Biological: bevacizumab</arm_group_label>
    <other_name>ONS-5010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active clinical diagnosis and OCT confirmation of one of the following retinal&#xD;
             disorders: exudative age-related macular degeneration (AMD), diabetic macular edema&#xD;
             (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the&#xD;
             Investigator, requires treatment with an anti-VEGF therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization&#xD;
&#xD;
          -  Previous use of Beovu®&#xD;
&#xD;
          -  Macular edema due to something other than exudative AMD, DME or BRVO, in the study eye&#xD;
&#xD;
          -  History of inadequate response to previous intravitreal anti-VEGF therapy&#xD;
&#xD;
          -  History of any intraocular or periocular corticosteroid injection or implant, in the&#xD;
             study eye&#xD;
&#xD;
          -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month&#xD;
             preceding randomization&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye that may require medical or&#xD;
             surgical intervention or contribute to vision loss during the study period&#xD;
&#xD;
          -  Active intraocular inflammation in the study eye&#xD;
&#xD;
          -  Current vitreous hemorrhage in the study eye&#xD;
&#xD;
          -  Polypoidal choroidal vasculopathy (PCV) in the study eye&#xD;
&#xD;
          -  History of idiopathic, infectious or autoimmune-associated uveitis in either eye&#xD;
&#xD;
          -  Current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis,&#xD;
             or endophthalmitis in either eye&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg&#xD;
             despite treatment with anti-glaucoma medication)&#xD;
&#xD;
          -  Premenopausal women not using adequate contraception&#xD;
&#xD;
          -  Current treatment for active systemic infection&#xD;
&#xD;
          -  Known allergy to any component of the study drug , not amenable to treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer M Kissner, PhD</last_name>
    <phone>609.619.3990</phone>
    <email>jenniferkissner@outlooktherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

